The historical rank and industry rank for Cardiff Oncology's Days Payable or its related term are showing as below:
During the past 13 years, Cardiff Oncology's highest Days Payable was 455.49. The lowest was 197.11. And the median was 229.13.
CRDF's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
Cardiff Oncology's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Cardiff Oncology Days Payable Related Terms
Cardiff Oncology Days Payable Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Days Payable distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cardiff Oncology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cardiff Oncology and its competitors. Over the past decade, Cardiff Oncology's Days Payable has ranged from 197.11 to 455.49. According to the industry distribution chart, Cardiff Oncology ranks #999999 out of 707 companies in the Biotechnology industry.
Is Cardiff Oncology's Days Payable too high?
Cardiff Oncology's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 197.11 to a high of 455.49. Based on the distribution chart, Cardiff Oncology ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardiff Oncology has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Days Payable compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #999999 out of 707 companies for Days Payable. This places Cardiff Oncology in the lower half of its industry. The industry median Days Payable is 113.76. Historically, Cardiff Oncology's own Days Payable has ranged from 197.11 to 455.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.48, compared to a current price of $1.25 — trading 15.5% below its estimated fair value. The current Days Payable is 0.00. Cardiff Oncology's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $1.25 is trading 15.5% below its estimated GF Value™ of $1.48.
GuruFocus considers Cardiff Oncology to be Modestly Undervalued.
Key valuation signals for CRDF:
Days Payable: 0.00
GF Value™: $1.48 vs. price of $1.25 (15.5% below fair value)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
53GF Score
Get the complete analysis for CRDF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
